Transactional

Life Sciences M&A in a holding pattern

Matthew Appleton

Continued uncertainty surrounding President Trump’s proposed tax reforms has slowed activity in the Life Sciences sector, with deal values holding well below the record levels seen in previous years. If Trump’s promised corporate tax cut materialises, big U.S. players may be encouraged to repatriate (and spend) the huge amounts of cash currently held offshore.  But Read More

UK Life Sciences companies need full-cycle support to grow

Matthew Appleton

Now that the dust is settling after the publication of the UK’s “Life Sciences: industrial strategy”, it seems a good time to focus on one of the report’s key themes – growth. The report rightly notes that despite the UK having a strong track record in Life Sciences companies emerging, very few of those have Read More

Italy unlocks corporate investments in retail pharmacies

Marco de Morpurgo

On 29 August 2017, significant regulatory changes allowing corporate entities to own retail pharmacy businesses will enter into force in Italy.  The new measures bring attractive opportunities for corporate investors, opening to new business models for Italian pharmacies that already exist in other EU countries, such as corporate-owned pharmacy retail chains.  To date, Italian law Read More

Restitution of enrichment by mistake – AstraZeneca recovers $2 million for candidate drugs mistakenly interpreted to be ‘Collaboration Compounds’

Robyn Trigg

In Astex Therapeutics v AstraZeneca, AstraZeneca were able to recover $2 million by way of restitution of enrichment for two milestone payments made to Astex by mistake under a collaboration agreement. Astex and AstraZeneca entered into an agreement to develop a BACE inhibitor for treatment of Alzheimer’s disease.  After expiry of the collaboration term, the Read More